Viral gene delivery

Bibliography

• JANE SM, CUNNINGHAM JM, VANIN EF: Vector develop- ment: a major obstacle in human gene therapy. Ann. Med. (1998) 30:413–415.
   PubMed Web of Science ®Google Scholar
• •Interesting perspective on vectors and gene therapy.
   Google Scholar
• ROBBINS PD, GHIVIZZANI SC: Viral vectors for gene therapy. Pharmacol. Ther. (1998) 80:35–47.
   PubMed Web of Science ®Google Scholar
• MORSY MA, CASKEY CT: Expanded-capacity adenoviral vectors-the helper-dependent vectors. Mol. Merl. Today (1999) 5:18–24.
   PubMedGoogle Scholar
• •Description of high-capacity adenovirus vectors.
   Google Scholar
• KLIMATCHEVA E, ROSENBLATT JD, PLANELLES V:Lentiviral vectors and gene therapy. Front. Biosci. (1999) 4:D481–D496.
   PubMedGoogle Scholar
• PATIJN GA, KAY MA: Hepatic gene therapy usingadeno-associated virus vectors. Semin. Liver Dis. (1999)19:61–69.
   PubMed Web of Science ®Google Scholar
• •State of the art review of AAV vectors for gene delivery to the liver, but applies to other organs as well.
   Google Scholar
• ONODERA M, NELSON DM, SAKIYAMA Y, CANDOTTI F, BLAESE RM: Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Acta Haematol. (1999) 101:89–96.
   PubMed Web of Science ®Google Scholar
• •Recent review by prominent group studying ADA deficiency and bone marrow stem cell-directed gene transfer.
   Google Scholar
• RABINOWITZ JE, SAMULSKI J: Adeno-associated virus expression systems for gene transfer. Curr. Opin. Biotechnol. (1998) 9:470–475.
   PubMed Web of Science ®Google Scholar
• •Review of AAV vectors.
   Google Scholar
• WIVEL NA, WILSON JM: Methods of gene delivery. Hematol Oncol. Gin. North Am. (1998) 12:483–501.
   PubMed Web of Science ®Google Scholar
• CRISTIANO RJ: Targeted, non-viral gene delivery for cancer gene therapy. Front. Biosci. (1998) 3:D1161–D1170.
   PubMedGoogle Scholar
• YONEMITSU Y, ALTON EW, KOMORI K, YOSHIZUMI T,SUGIMACHI K, KANEDA Y: HVJ (Sendai virus) liposome-mediated gene transfer: current status and future perspectives. Int. J. Oncol. (1998) 12:1277–1285.
   PubMedGoogle Scholar
• CURTIN ME: Retrovirus vectors for mammalianengineering. Microbiol Sci. (1984) 1:210
   PubMedGoogle Scholar
• BLAESE RM, CULVER KW, MILLER AD et al.: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science (1995) 270:475–480.
   PubMed Web of Science ®Google Scholar
• ••Important description of major clinical trial of gene therapyfor severe immune deficiency in humans.
   Google Scholar
• WILKE M, BOUT B, VERBEEK E et al.: Amphotropic retroviruses with a hybrid long terminal repeat as a tool for gene therapy of cystic fibrosis. Biochem. Biophys. Res. Commun. (1992) 187:187–194.
   PubMed Web of Science ®Google Scholar
• OHNO K, BROWN GD, MERUELO D: Cell targeting for gene delivery: use of fusion protein containing the modified human receptor for ecotropic murine leukemia virus. Biochem. Mol. Merl. (1995) 56:172–175.
   PubMed Web of Science ®Google Scholar
• YOSHIDA Y, EMI N, HAMADA H: VSV-G-pseudotyped retroviral packaging through adenovirus-mediated inducible gene expression. Biochem. Biophys. Res. Commun. (1997) 232:379–382.
   PubMed Web of Science ®Google Scholar
• MILLER DG, ADAM MA, MILLER AD: Gene transfer by retrovirus vectors occurs only in cells that are actively dividing at the time of infection. Mol. Cell. Biol. (1990) 10:4239–4242.
   PubMed Web of Science ®Google Scholar
• ROTHER RP, FODOR WL, SPRINGHORN JP et al.: A novelmechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J. Exp. Med. (1995) 182:1345–1355.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI, Y, COSSET, FL, LACHMANN, PJ, OKADA, H,WEISS, RA, COLLINS, MK: Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol (1994) 68:8001–8007.
   PubMed Web of Science ®Google Scholar
• KOHN DB, WEINBERG KI, NOTLA JA et al: Engraftmentof gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Merl. (1995) 1:1017–1023.
   PubMed Web of Science ®Google Scholar
• ENGEL BC, KOHN DB: Stem cell directed gene therapy.Front. Biosci. (1999) 4:e26–e33.
   PubMedGoogle Scholar
• KEMPLER G, FREITAG B, BERWIN B, NANASSY 0, BARKLIS E: Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site. Virology (1993) 193:690–699.
   PubMed Web of Science ®Google Scholar
• HESDORFFER C, MARKOWITZ D, WARD M, BANK A: Somatic gene therapy. Hematol. Oncol. Clin. North Am. (1991) 5:423–432.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ DG, GOFF, SP, BANK A: Safe and efficient ecotropic and amphotropic packaging lines for use in gene transfer experiments. Trans. Assoc. Am. Physicians. (1988) 101:212-218, 1988.
   Google Scholar
• ANDERSON WF, KANTOFF P, EGLITIS M et al.: Gene transfer and expression in nonhuman primates using retroviral vectors. Cold Spring Harb. Symp. Quant. (1986) 51 (Pt 2):1073–1081.
   PubMedGoogle Scholar
• ROTHER RP, SQUINTO SP, MASON JM, ROLLINS SA: Protection of retroviral vector particles in human blood through complement inhibition. Hum. Gene. Ther. (1995) 6:429–435.
   PubMed Web of Science ®Google Scholar
• CONE RD, MULLIGAN RC: High-efficiency gene transferinto mammalian cells: Generation of helper-free recombinant retrovirus with broad mammalian host range. Proc. Natl. Acad. Sci. USA (1984) 81(20):6349–6353.
   PubMed Web of Science ®Google Scholar
• YEE J-K, MIYANOHARA A, LAPORTE P, BOUIC K, BURNS JC, FRIEDMANN T: A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA (1994) 91: 9564–9568.
   PubMed Web of Science ®Google Scholar
• •Important approach to the production of high-titre retroviral vectors by special pseudotyping.
   Google Scholar
• EZZEDDINE ZD, MARTUZA RL, PLATIKA D, SHORT MP, MALICK A, CHOI B, BREAKEFIELD XO: Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. (1991) 3:608–614.
   PubMedGoogle Scholar
• SHORT MP, CHOI BC, LEE JK, MALICK A, BREAKEFIELD XO, MARTUZA RL: Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. (1990) 27:427–439.
   PubMed Web of Science ®Google Scholar
• •Description of the use of packaging cells directly to inhibit tumour cell growth in the central nervous system.
   Google Scholar
• STEVENSON SC, ROLLENCE M, MARSHALL-NEFF J, MCCLELLAND A: Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J. Virol. (1997) 71:4782–4790.
   PubMed Web of Science ®Google Scholar
• WICKHAM TJ, CARRION ME, KOVESDI I: Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. (1995) 2:750–756.
   PubMed Web of Science ®Google Scholar
• CHENGALVALA MV, LUBECK MD, SELLING BJ et al: Adenovirus vectors for gene expression. Curr. Opin. Biotechnol. (1991) 2:718–722.
   PubMedGoogle Scholar
• HOFFMAN M: New vector delivers genes to lung cells.Science. (1991) 252:374.
   PubMed Web of Science ®Google Scholar
• TRAPNELL BC, GORZIGLIA M: Gene therapy using adenoviral vectors. Curr. Opin. BiotechnoL (1994) 5:617–625.
   PubMedGoogle Scholar
• GINSBERG HS: The ups and downs of adenovirus vectors. Bull NY Acad. Med. (1996) 73:53–58.
   PubMedGoogle Scholar
• •Candid discussion of the travails of adenoviral vector gene delivery.
   Google Scholar
• GORZIGLIA MI, KADAN MJ, YEI S, LIM J, LEE GM, LUTHRA R, TRAPNELL BC: Elimination of both El and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. (1996) 70:4173–4178.
   PubMed Web of Science ®Google Scholar
• •Good illustration of the advantages of using larger deletion derivatives of adenovirus as gene delivery vectors.
   Google Scholar
• ENGELHARDT JF, YE X, DORANZ B, WILSON JM: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sc1 USA. (1994) 91:6196–6200.
   PubMed Web of Science ®Google Scholar
• •Another interesting description of larger deletions made in the Ad genome and the results of using such vectors.
   Google Scholar
• MITTEREDER N, MARCH KL, TRAPNELL BC: Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. (1996) 70:7498–7509.
   PubMed Web of Science ®Google Scholar
• QUANTIN B, PERRICAUDET LD, TAJBAKHSH S, MANDEL JL: Adenovirus as an expression vector in muscle cells in vivo. Proc. Nati Acad. Sci. USA. (1992) 89:2581–2584.
   PubMed Web of Science ®Google Scholar
• LEE LY, POLCE DR, EL-SAWY T, HACKETT NR, ROSENGART TK, CRYSTAL RG: Influence of pre-immunization iwth wild type adenovirus on adenovirus vector-mediated expression of the vascular endothelial growth factor 121 cDNA. Am. Soc. Gene Ther. Proc. (1999) 2:110a.
   Google Scholar
• YANG Y, LI Q, ERTL HC, WILSON JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombi-nant adenoviruses. j Virol. (1995) 69:2004–2015.
   PubMed Web of Science ®Google Scholar
• ••Mechanistic study of the nature of the immune response toadenoviral vectors and consequent limitations of adenovirus gene delivery.
   Google Scholar
• KASS-EISLER A, FALCK-PEDERSEN E, ELFENBEIN DH et al.: The impact of developmental stage, route of admini-stration and the immune system on adenovirus-mediated gene transfer. Gene Ther. (1994) 1:395–402.
   PubMed Web of Science ®Google Scholar
• ENGELHARDT JF, LITZKY L, WILSON JM: Prolonged transgene expression in cotton rat lung with recombi-nant adenoviruses defective in E2a. Hum. Gene Ther. (1994) 5:1217–1229.
   PubMed Web of Science ®Google Scholar
• DEDIEU JF, VIGNE E, TORRENT C et al.: Long-term gene delivery into the livers of immunocompetant mice with El/E4-defective adenoviruses. j Vim]. (1997) 71:4626–4637.
   Web of Science ®Google Scholar
• CRYSTAL RG, MCELVANEY NG, ROSENFELD MA et al.: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet. (1994) 8:42–51.
   PubMed Web of Science ®Google Scholar
• •Adenovirus gene delivery to treat cystic fibrosis in human trials. WILSON JM: Adenoviruses as gene-delivery vehicles. N Engl. J. Med. (1996) 334:1185-1187. ALTON E, GEDDES D: A mixed message for cystic fibrosis gene therapy. Nature Genet. (1994) 8:8-9. CRYSTAL RG: In vivo and ex vivo gene therapy strate-gies to treat tumors using adenovirus gene transfer vectors. Cancer Chemother. Pharmacol. (1999) 43:S90-S99. Discussion of cancer gene therapy using adenovirus vectors.
   Google Scholar
• BILBAO G, GOMEZ-NAVARRO J, CURIEL DT: Targeted adenoviral vectors for cancer gene therapy. Adv. Exp. Med. Biol. (1998) 451:365–374.
   PubMed Web of Science ®Google Scholar
• •Good review of cancer gene therapy using adenoviral vectors.
   Google Scholar
• Stewart, PL, Chiu, CY, Huang, S, et al.: Cryo-EM visualiza-tion of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO J. (1997) 16:1189–1198.
   Google Scholar
• GOLDMAN MJ, WILSON JM: Expression of alpha v beta 5integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J. Vim]. (1995) 69:5951–5958.
   Web of Science ®Google Scholar
• FISHER KJ, CHOI H, BURDA J, CHEN SJ, WILSON JM:Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. (1996) 217:11–22.
   PubMed Web of Science ®Google Scholar
• •Gutless adenovirus vectors.
   Google Scholar
• POTTER MA, CHANG PL: The use of immunosuppres-sive agents to prevent neutralizing antibodies against a transgene product. Ann. NY Acad. Sci. (1999) 875:159–174.
   PubMed Web of Science ®Google Scholar
• ILAN Y, ATTAVAR P, TAKAHASHI M et al: Induction ofcentral tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J. Clin. Invest. (1996) 98:2640–2647.
   PubMed Web of Science ®Google Scholar
• •Modulation of the immune response vs. adenovirus using unusual inoculation approach.
   Google Scholar
• BERNS KI, GIRAUD C: Adeno-associated virus life cycle.Curr. Top. Microbic)]. Immunol. (1996) 218:1–23.
   PubMed Web of Science ®Google Scholar
• KOTIN RM, MENNINGER JC, WARD DC, BERNS KI: Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics (1991) 10:831–834.
   PubMed Web of Science ®Google Scholar
• SUMMERFORD C, SOMULSKI RJ: Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus Type 2 virions. J. Virol. (1998) 72:1438–1445.
   PubMed Web of Science ®Google Scholar
• SUMMERFORD C, BARTLETT JS, SOMULSKI RJ: AlphaV85integrin: a co-receptor for adeno-associated virus Type 2 infection. Nature Med. (1999) 5:78–82.
   PubMed Web of Science ®Google Scholar
• •Coreceptor for AAV, required for entry into target cells.
   Google Scholar
• QING K, MAH C, HANSEN J, ZHOU S, DWARKI V, SRIVAS- TAVA A: Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Med. (1999) 5:71–77.
   PubMed Web of Science ®Google Scholar
• •Coreceptor for AAV, required for entry into target cells.
   Google Scholar
• PONNAZHAGAN S, MUKHERJEE P, WANG XS et al: Adeno-associated virus Type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J. Vim]. (1997) 71:8262–8267.
   Web of Science ®Google Scholar
• ••Elucidation of the mechanism underlying variability of AAVtransduction of hematopoietic progenitor cells.
   Google Scholar
• TREMPE JP: Packaging systems for adeno-associatedvirus vectors. Curr. Top. Microbiol. Immunol. (1996) 218:35–49.
   PubMed Web of Science ®Google Scholar
• GRIMM D, KERN A, RITTNER K, KLEINSCHMIDT JA: Noveltools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. (1998) 9:2745–2760.
   PubMed Web of Science ®Google Scholar
• INOUE N, RUSSELL DW: Packaging cells based oninducible gene amplification for the production of adeno-associated virus vectors. J. Virol. (1998) 72:7024–7031.
   PubMed Web of Science ®Google Scholar
• •Packaging cells for AAV vectors using an inducible expres-sion system.
   Google Scholar
• WU P, PHILLIPS MJ, BUI J, TERWILLIGER EF: Adeno- associated virus vector-mediated transgene integra-tion into neurons and other nondividing cell targets. J. Virol. (1998) 72:5919–5926.
   PubMed Web of Science ®Google Scholar
• •AAV integration.
   Google Scholar
• MALIK P, MCQUISTON SA, YU XJ, PEPPER KA et al: Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration into the K562 human hematopoietic cell line. J. Virol. (1997) 71:1776–1783.
   PubMed Web of Science ®Google Scholar
• •Limits on AAV integration.
   Google Scholar
• HERZOG RW, YANG EY, COUTO LB et al.: Long-term correction of canine hemophilia B by gene transfer of blood coagulation Factor IX mediated by adeno-associated viral vector. Nature Med. (1999) 5:56–63.
   PubMed Web of Science ®Google Scholar
• ••Correction of haemophilia B using AAV-delivered Factor IXin an animal model of the human disease.
   Google Scholar
• LEWIN, AS, DRENSER, KA, HAUSWIRTH, WW et al: Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nature Med. (1998) 4:967–971.
   PubMed Web of Science ®Google Scholar
• •AAV rectification of retinitis pigmentosa using a ribozyme strategy.
   Google Scholar
• CHEN WY, BAILEY EC, MCCUNE SL, DONG JY, TOWNESTM: Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. USA (1997) 94:5798–5803.
   PubMed Web of Science ®Google Scholar
• DOLL RF, CRANDALL JE, DYER CA, AUCOIN JM, SMITH Fl:Comparison of promoter strengths on gene delivery into mammalian brain cells using AAV vectors. Gene Ther. (1996) 3:437–447.
   PubMed Web of Science ®Google Scholar
• CHAMGERLIN NL, DU B, DE LACALLE S, SAPER CB: Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in CNS. Brain Res. (1998) 793:169–175.
   PubMed Web of Science ®Google Scholar
• DALY TM, VOGLER C, LEVY B, HASKINS ME, SANDS MS:Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA (1999) 96:2296–2300.
   PubMed Web of Science ®Google Scholar
• DUDUS L, ANAND V, ACLAND GM et al.: Persistenttransgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res. (1999) 39:2545–2553.
   PubMed Web of Science ®Google Scholar
• BEATON A, PALUMBO P, BERNS KI: Expression of the AAV p5 and p19 promoters is negatively regulated in trans by the rep protein. J. Vim]: (1989) 63:4450-4454. HERMONAT PL, QUIRK JG, BISHOP BM, HAN L: The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors. FEBS Lett. (1997) 407:78–84.
   Google Scholar
• •Interesting twist on AAV vectors.
   Google Scholar
• SHIMADA T, FUJII H, MITSUYA H, NIENHUIS AW: Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. J. Clin. Invest. (1991) 88:1043–1047.
   PubMed Web of Science ®Google Scholar
• AKKINA RK, WALTON RM, CHEN ML, LI Q-X, PLANELLES V, CHEN ISY: High efficiency gene transfer into CD34+ cells with a human immunodeficiency virus Type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Vim]. (1996) 70:2581–2585.
   Web of Science ®Google Scholar
• •HIV-derived lentivirus vectors and their production by pseudotyping with VSV-G.
   Google Scholar
• NALDINI L, BLOMER U, GALLAY P et al: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263–267.
   PubMed Web of Science ®Google Scholar
• •Use of HIV-derived vectors to deliver transgenes to quiescent cells.
   Google Scholar
• GIANNOUKAKIS, N, MI, Z, GAMBOTTO, A eta].: Infection of intact human islets by a lentiviral vector. Gene Ther. (1999) 6:1545–1551.
   Google Scholar
• EVANS JT, KELLY PF, O'NEILL E, GARCIA JV: Human cord blood CD34+CD38- cell transduction via lentivirus-based gene transfer vectors. Hum. Gene Ther. (1999) 10: 1479–1489.
   PubMed Web of Science ®Google Scholar
• OLSEN JC: Gene transfer vectors derived from equineinfectious anemia virus. Gene Ther. (1998) 5:1481–1487.
   PubMed Web of Science ®Google Scholar
• •Alternative lentivirus vector.
   Google Scholar
• WU M, MERGIA A: Packaging cell lines for simian foamy virus Type I vectors. J. Virol (1999) 73:4498–4501.
   PubMed Web of Science ®Google Scholar
• •Alternative lentivirus vector.
   Google Scholar
• UNUTMAZ D, KEWALRAMANI VN, MARMON S, LITTMAN DR: Cytokine signals are sufficient for HIV-1 infection of resting T lymphocytes. J. Exp. Med. (1999) 189: 1735–1746.
   PubMed Web of Science ®Google Scholar
• •Lentiviruses do not transduce all resting cells equally well, and some must be stimulated in order to achieve transduction.
   Google Scholar
• YANG Y, VANIN EF, WHITT MA et al.: Inducible,high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum. Gene Ther. (1995) 6:1203–1213.
   PubMed Web of Science ®Google Scholar
• ORY DS, NEUGEBOREN BA, MULLIGAN, RC: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA (1996) 93:11400–11406.
   PubMed Web of Science ®Google Scholar
• DALYOT-HERMAN N, BEN-NUN-SHAUL 0, GORDON-SHAAG A, OPPENHEIM A: The simian virus 40 packaging signal ses is composed of redundant DNA elements which are partly interchangeable. J. Mol Biol. (1996) 259:69–80.
   PubMed Web of Science ®Google Scholar
• BUTEL JS, JARVIS DL: The plasma-membrane-associatedform of SV40 large tumor antigen: biochemical and biological properties. Biochim. Biophys. Acta. (1986) 865: 171–195.
   PubMed Web of Science ®Google Scholar
• GOODING LR: Specificities of killing by cytotoxiclymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J. Immunol. (1977) 118: 920–927.
   PubMed Web of Science ®Google Scholar
• BREAU WC, ATWOOD WJ, NORKIN LC: Class I major histocompatibility protein share an essential component of the simian virus 40 receptor. J. Vim]. (1992) 66:2037–2045.
   Web of Science ®Google Scholar
• •The receptor for 5V40 is MHC, class I.
   Google Scholar
• STANG E, KARTENBECK J, PARTON RG: Major histocom-patibility complex class I molecules mediate associa-tion of SV40 with caveolae. Mol. Biol. Cell. (1997) 8:47–57.
   PubMed Web of Science ®Google Scholar
• STRAYER DS, KONDO R, MILANO J, DUAN L-X: Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Ther. (1997) 4:219–225.
   PubMed Web of Science ®Google Scholar
• •Description of the utility of rSV40 vectors for gene delivery to unstimulated human peripheral blood cells.
   Google Scholar
• BOUHAMDAN M, DUAN L-X, POMERANTZ RJ, STRAYER DS: Inhibition of HIV-1 by anti-integrase single-chain variable fragment (SFO: Delivery by SV40 provides durable protection against HIV-1 and does not require selection. Gene Ther. (1999) 6:660–666.
   PubMed Web of Science ®Google Scholar
• ZERN M, OZAKI I, DUAN L-X, POMERANTZ R, LIU S-L, STRAYER DS: A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther. (1999) 6:114-120(1999).
   Google Scholar
• •Successful delivery of a ribozyme that targets a transcript expressed at very high levels in cultured hepatocytes.
   Google Scholar
• STRAYER DS, MILANO J: SV40 mediates stable gene transfer in vivo. Gene Ther. (1996) 3:581–587.
   PubMed Web of Science ®Google Scholar
• STRAYER DS: SV40 as an effective gene transfer vector in vivo. J. Biol. Chem. (1996) 271:24741–24746.
   PubMed Web of Science ®Google Scholar
• KONDO R, FEITELSON MA, STRAYER DS: Use of SV40 to immunize against hepatitis B surface antigen: Implica-tions for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Ther. (1998) 5:575–582.
   PubMed Web of Science ®Google Scholar
• SZCZYPKA MS, MANDEL RJ, DONAHUE BA, SNYDER RO, LEFF SE, PALMITER RD: Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron (1999) 22:167–178.
   PubMed Web of Science ®Google Scholar
• HARDING TC, GEDDES BJ, MURPHY D, KNIGHT D, UNEY JB: Switching transgene expression in the brain using an adenoviral tetracycline-regulaTable system. Nature Biotechnol (1998) 16:553–555.
   PubMed Web of Science ®Google Scholar
• HO DY, MCLAUGHLIN JR, SAPOLSKY RM: Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system. Brain Res. Mol. Brain Res. (1996) 41: 200–209.
   PubMedGoogle Scholar
• CORTI 0, SANCHEZ-CAPELO A, COLIN P, HANOUN N,HAMON M, MALLET J: Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (1999) 96:12120–12125.
   PubMed Web of Science ®Google Scholar
• GLORIOSO JC, DELUCA NA, FINK DJ: Development and application of Herpes simplex virus vectors for human gene therapy. Ann. Rev. Microbic)]. (1995) 49:675–710.
   PubMed Web of Science ®Google Scholar
• LACHMANN RH, EFSTATHIOU S: Use of herpes simples virus Type 1 for transgene expression within the central nervous system. Clin. Sci. (1999) 96:533–541.
   PubMed Web of Science ®Google Scholar
• GLORIOSO JC, GOINS WE, SCHMIDT MC, OLIGINO T et al: Engineering herpes simplex virus vectors for human gene therapy. Adv. Pharmacol. (1997) 40:103–136.
   PubMedGoogle Scholar
• EFSTATHIOU S, MINSON AC, FIELD HJ, ANDERSON JR, WILDY P: Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans. J. Virol. (1986) 57:446–455.
   PubMed Web of Science ®Google Scholar
• CROEN KD, OSTROVE JM, DRAGOVIC LJ, SMIALEK JE, STRAUSE SE: Latent herpes simplex virus in human trigeminal ganglia. Detection of an immediate early gene 'anti-sense' transcript by in situ hybridization. N Eng]. J. Med. (1987) 317:1427–1432.
   Google Scholar
• BATCHELOR AH, O'HARE PO: Regulation and type-specific activity of a promoter located upstream of the latency-associated transcript of herpes simplex virus Type 1. J. Vim]. (1990) 64:3269–3279.
   Web of Science ®Google Scholar
• ZWAAGSTRA JC, GHIASI H, NESBURN AB, WECHSLER SL: In vitro promoter activity associated with the latency-associated transcript of herpes simplex virus Type 1.1 Gen. Virol. (1989) 70:2163–2169.
   PubMed Web of Science ®Google Scholar
• FINK DJ, STERNBERG R, WEBER PC, MATA M, GOINS WF, GLORIOSO JC: In vivo expression of 0-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum. Gene Ther. (1992) 3:11–19.
   PubMed Web of Science ®Google Scholar
• DOBSON AT, MARGOLIS TP, SEDERATI F, STEVENS JG, FELDMAN LT: A latent, non-pathogenic HSV-1-derived vector stably expresses 8-galactosidase in mouse neurons. Neuron (1990) 5:353–360.
   PubMed Web of Science ®Google Scholar
• HO DY, MOCARSKI ES, SAPOLSKY RM: Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc. Natl. Acad. Sci. USA (1993) 90:3655–3659.
   PubMed Web of Science ®Google Scholar
• CHIOCCA AE, CHOI BB, CAI W, DELUCA NA, SHAFFER PA et al.: Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol. (1990) 2:739–746.
   PubMedGoogle Scholar
• FINK DJ, POLIANI PL, OLIGINO T, KRISKY DM, GOINS WF, GLORIOSO JC: Development of an HSV-based vector for the treatment of Parkinson's disease. Exp. Neurol. (1997) 144:103–121.
   PubMed Web of Science ®Google Scholar
• OROSKAR AA, READ GS: Control of mRNA stability by the virion host shutoff function of herpes simplex virus. J. Virol. (1989) 63:1897–1906.
   PubMed Web of Science ®Google Scholar
• SANDRI-GOLDIN RM, MENDOZA GE: A herpesvirus regulatory protein appears to act post-transcriptionally by affecting mRNA processing. Genes Dev. (1992) 6:848–863.
   PubMed Web of Science ®Google Scholar
• SMITH IL, HARDWICKE MA, SANDRI-GOLDIN RM: Evidence that herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology (1992) 186:74–86.
   PubMed Web of Science ®Google Scholar
• DUBENSKY TW, JR DRIVER DA POLO JM et al.: Sinbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. (1996) 70:508–519.
   Google Scholar
• OHE Y, ZHAO D, SAIJO N, PODACK ER: Construction of a novel bovine papillomavirus vector without detect-able transforming activity suitable for gene transfer. Hum. Gene Ther. (1995) 6:325–333.
   PubMed Web of Science ®Google Scholar
• CHU TH, DORNBURG R: Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J. Virol. (1997) 71:720–725.
   PubMed Web of Science ®Google Scholar